Abstract

Fulminant hepatic failure due to acute massive liver cell necrosis is a complex pathophysiological entity, and treatment is still unsatisfactory. Artificial liver supports such as hemodialysis, hemoperfusion, and plasmapheresis have recently been used clinically to treat fulminant hepatic failure. However, survival rate has not improved as expected, although the consciousness of the patient has improved frequently. In this article the present status of clinical artificial liver support and basic research of hybrid artificial liver will be discussed. Moreover, the future aspects of total artificial liver support and hepatocyte transplantation for chronic liver failure will be introduced.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call